Novartis in up to $1 billion deal to acquire ex-US rights to Fovista – The Pharma Letter

Novartis in up to $1 billion deal to acquire ex-US rights to Fovista
The Pharma Letter
Fovista is being studied in combination with anti-VEGF agents for patients suffering from wet age-related macular degeneration (wet AMD). Novartis will also develop a co-formulation of Fovista with a Novartis proprietary anti-VEGF treatment. Ophthotech

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment